Motivation: 1 in 4 adult patients in the US experience symptoms of gastroparesis – pain, bloating, nausea and vomiting – with the incidence growing rapidly due to the increasing diabetic population [1,2]. A safe and effective treatment that can be taken on a chronic basis remains a significant unmet need.
Lead Program(s): CIN-102 (deudomperidone) is a Dopamine 2/3 antagonist with prokinetic and antiemetic effects being developed to treat patients with gastrointestinal disorders currently in phase 2 of clinical development. CIN-102 has secured composition of matter patents as well as completed a proof-of-concept study showing signals of improvement in nausea and vomiting and promising effect on gastric emptying in patients with gastroparesis.
 Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Digestive Diseases and Sciences. 1993;38(9):1569–1580.
 Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clinical Gastroenterology and Hepatology. 2005;3(6):543–552.